Department of Pulmonology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Lung Cancer. 2010 May;68(2):283-7. doi: 10.1016/j.lungcan.2009.06.021. Epub 2009 Jul 25.
Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients.
46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human beta-globin gene. Survival analysis was performed using the Kaplan-Meier method and compared with a Cox-regression analysis.
The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55ng/ml versus 23ng/ml, p=0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found.
In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients.
循环血浆 DNA 在肺癌患者中的浓度明显高于对照组。关于循环 DNA 作为预后因素的报告存在矛盾。本研究旨在前瞻性分析循环血浆 DNA 与未经治疗的非小细胞肺癌 (NSCLC) 患者总生存期 (OS) 的关系。
分析了 46 名未经治疗的 NSCLC 患者和 21 名对照者，随访时间为 6.5 年。通过针对人β-球蛋白基因的实时定量聚合酶链反应 (qPCR) 定量基线循环血浆 DNA。使用 Kaplan-Meier 方法进行生存分析，并与 Cox 回归分析进行比较。
死亡患者的 DNA 浓度中位数（87%）明显高于随访结束时存活患者（87ng/ml 比 55ng/ml，p=0.02）。在 DNA 浓度较高的患者中，总生存率明显较差。在这项研究中，未发现 DNA 浓度与肿瘤特征、年龄、性别或肺部炎症状况有关。
在这项研究中，NSCLC 患者诊断时高循环血浆 DNA 浓度是生存较差的预后因素。循环 DNA 可用作 NSCLC 患者预后特征的非侵入性生物标志物。
